BioNxt advances sublingual everolimus ODF; large-animal PK study begins
BioNxt is advancing its sublingual everolimus ODF for organ transplant rejection and has initiated a large-animal pharmacokinetic study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.